Shanghai Allist Pharmaceuticals (688578) Q1 2026 earnings summary

Executive summary

• Achieved revenue of RMB 1.58 billion in Q1 2026, up 44.19% year-over-year, driven by strong sales of three key oncology drugs following inclusion in the national medical insurance directory.

• Net profit attributable to shareholders reached RMB 636 million, a 54.94% increase year-over-year.

• Continued focus on innovation and R&D in oncology, with expanded patient coverage and product approvals.

Financial highlights

• Operating income: RMB 1.58 billion, up 44.19% year-over-year.

• Net profit attributable to shareholders: RMB 636 million, up 54.94% year-over-year.

• Operating cash flow: RMB 554 million, up 41.06% year-over-year.

• Basic and diluted EPS: RMB 1.41, up 54.94% year-over-year.

• R&D investment: RMB 128 million, up 14.09% year-over-year, representing 8.08% of revenue.

Outlook and guidance

• Plans to further strengthen commercialization and academic promotion of oncology products.

• Aims to leverage differentiated product advantages and expand patient benefit.